Rheumatology

Latest News

Data highlights motor function improvements with ELEVIDYS treatment | Image Credit: © Colored Lights - © Colored Lights - stock.adobe.com.
Duchenne muscular dystrophy gene therapy demonstrates improved motor functions

May 16th 2025

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study.

Elamipretide to treat Barth syndrome sees FDA target action delay | Image Credit: © Araki Illustrations - © Araki Illustrations  - stock.adobe.com.
Elamipretide to treat Barth syndrome sees FDA target action delay

April 30th 2025

FDA approves nipocalimab-aahu to treat generalized myasthenia gravis | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves nipocalimab-aahu to treat generalized myasthenia gravis

April 30th 2025

Navepegritide NDA submitted to treat children with achondroplasiaLatest revision | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
Navepegritide NDA submitted to treat children with achondroplasia

March 31st 2025

FDA approves fitusiran for hemophilia A, B patients aged 12 years and upLatest revision | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves fitusiran for hemophilia A, B patients aged 12 years and up

March 28th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.